

University of Michigan Rogel Cancer Center



The U-M Rogel Cancer Center is one of only 47 centers in the United States to earn the **National Cancer Institute's "comprehensive" designation**. This prestigious designation reflects our wide-ranging research initiatives, including translating new discoveries from the laboratory to our patients. We also conduct research to better prevent or control cancer and provide patient education, community outreach and training for tomorrow's cancer experts.

The Cancer Center is also a founding member of the **National Comprehensive Cancer Network**, a consortium of 30 of the nation's premier centers, which develops national guidelines for the delivery of effective, quality care.

Rogel Cancer Center provides outpatient oncology care at multiple centers in the Southeast Michigan area. Pharmacists are embedded in specialty clinics at the main Ann Arbor campus and the Brighton Center for Specialty Care. Nine pharmacy specialists serve the outpatient clinics, including the expansion of services to pediatric hematology/oncology clinic in 2020.

Here's a snapshot of our annual clinical activities:

- Over 130,000 outpatient visits
- Over 63,000 infusion treatments
- Over 1,000 patients enrolled in clinical trials

The University of Michigan and C.S. Mott Children's Hospital have become a **center of excellence for high-risk pediatric brain tumors**. In 2019, Michigan was added as a member of the Pacific Neuro-Oncology Consortium (PNOC). Researchers and pharmacists at Michigan developed the CNS TAP predictive tool to determine optimal targeted therapy for neuro-oncology patients.

Michigan is home to a **Specialized Programs of Research Excellence (SPORE)** in prostate cancer. These significant, multi-year NCI research grants focus on prevention, early detection, diagnosis and treatment of a specific cancer type.

Our patients are the most important beneficiaries of Michigan's vigorous commitment to research. Through more than **350 active cancer-related clinical trials**, patients have access to the very latest treatment advances, often before they are available in the community.

Pharmacy residents contribute to practice-changing research in collaboration with U-M pharmacists and oncologists.

Notable recent resident-led research projects include:

- Weis TM, Marini BL, Nachar VR, et al. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. *Leuk Lymphoma* 2020.
- Tam AH, Schepers AJ, Qin A, Nachar VR. Impact of extended-interval versus standard dosing of zoledronic acid on skeletal events in non-small-cell lung cancer and small-cell lung cancer patients with bone metastases. *Ann Pharmacother* 2020.
- Reid JH, Perissinotti AJ, Benitez LL, et al. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. *Leuk Lymphoma* 2020.

